Please cite this article in press E.Honey et al., A Review Article On Recent Changes In Fluoroquinolones., Indo Am. J. P. Sci, 2024; 11 (01).

[1] F. E. G. M. B. J. B. R. Lesher GY, “1,8-Naphthyridine derivatives: a new class of chemotherapeutic agents,” J Med Pharm Chem, p. 5:1063–8, 1962.
[2] M. J. E. V. T. P. Bambeke VF, “Quinolones in 2005: an update,” Clin Microbiol Infect, p.11:256–80, 2005.
[3] B. VF, “Renaissance of antibiotics against difficult infections:focus on oritavancin and new ketolides and quinolones,” Ann Med, p. 46:512–29, 2014.
[4] R. V. V. K. A. T. S. S. K. J. M. J. A. A. Madaan, Pharm, pp. 348,837, 2015.
[5] M. P. W. A. S. Wagman, “Quinolone Antibacterial Agents,Comprehensive Medicinal Chemistry II, 2nd edn,” (Eds: J. B. Taylor, D. J.Triggle), Elsevier, Amesterdam, pp. 567-596, 2007.
[6] A. I. S. M. S. S. T. I. H. Koga, J. Med. Chem, pp. 23,1358, 1980.
[7] S. Z. Z. X. Z.-S. L. M.-L. L. L.-S. F. E. Y.-Q. Hu, J.Med.Chem, pp. 141,335, 2017.
[8] A. J. S. J. R. P. M. S. Y. P. C. Sharma, J Enzyme Inhib. Med.Chem, pp. 25,577, 2010.
[9] S.-E. P. G. E.-D. A. A. A.-R. M. A. S. Y. M. Abdel-Aziz, J.Med.Chem, pp. 69,427, 2013.
[10] R. J. P. K. S. G. B. L. S. B. N. R. J. V. N. S. B. V. B. R. K. Shandil, “Antimicrob,” Agents Chemother, pp. 51,576, 2007.
[11] A. L. M. R. D. G. L. D. T. Gumbo, Antimicrob. Agents Chemother, pp. 49,3178, 2005.
[12] A. A. M. Daneshtalab, J.Pharm. Pharm.Sci, pp. 15,52, 2011.
[13] S. L. C. B. H. L. P. G. J. Li, J.Mol.Graph.Model, pp. 44,266, 2013.
[14] V. L. L. I. I. T. A. I. B. R. M. Pudlo, “Bioorg,” Med.Chem, pp. 22,2496, 2014.
[15] T. P. Bambeke VF, “Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes,” Drug Saf, p. 32:359–78, 2009.
[16] A. G. F. A. F. A. Sousa J, “Third and fourth generation fluoroquinolone antibacterials: a systemic review of safety and toxicity profiles,” Curr Drug Saf, p. 9:89–105, 2014.
[17] B. G. P. M. R. J. Wright DH, “Application of fluoroquinolone pharmacodynamics,” J Antimicrob Chemother, p. 46:669–83, 2000.
[18] C. P. G. M. M. M. W. P. G. T. L. A. J. Davenport JM, “Summary of pharmacokinetics and tissue distribution of a broad-spectrum fluoroquinolone,” JNJ-Q2. Clin Pharmacol Drug Dev,
p. 1:121– 30, 2012.
[19] B. M. H. J. H. A. L. D. M. M. H. S. Lawrence L, “In: Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects,” Proceedings of the 51st interscience conference of antimicrobial agents and chemotherapy,Chicago,USA,September, p. 17–20, 2011.
[20] A. A. V. A. H. H. S. W. S. M.-L. L. P. R. L. H. Patel H, “Human pharmacokinetics and safety profile of finafloxacin a new fluoroquinolone antibiotic in healthy volunteers,” Antimicrob Agents Chemother, p. 55:4386–93, 2011.
[21] K. S. S. K. L. C. L. K. Y. K. C. J. Han HK, “Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet.,” Curr Med Res Opin, p. 29:1349–55, 2013.
[22] N. R. Cozzarelli, Science, pp. 207,953, 1980.
[23] F. Z. R. J. N. J. D. Walters, Antimicrob. Agents Chemother, pp. 43,2710, 1999.
[24] F. Schmitz, J. Antimicrob. Chemother, pp. 41,481, 1998.J. S. I. M. A. Gutierrez, Antibiotics, pp. 7,32, 2018.S. Scroggs, C. Andrade, R. Chinnasamy, S. Azar, E. Schirtzinger, E. Garcia, J. Arterburn, K. Hanley and S. Rossi, “Old Drugs with New Tricks: Efficacy of Fluoroquinolones to Suppress Replication of Flaviviruses,” Viruses, pp. 12,1022, 2020.
[25] S. Scroggs, J. Gass, R. Chinnasamy, S. Widen, S. Azar, S. Rossi, J. Arterburn, N. Vasilakis and K. Hanley, “Evolution of resistance to fluoroquinolones by dengue virus serotype 4 provides insight into mechanism of action and consequences for viral fitness,” Virology, 552, 94–106, 2021.
[26] Y.-P. Xu, Y. Qiu, B. Zhang, G. Chen, Q. Chen, M. Wang, F. Mo, J. Xu, J. Wu, R.-R. Zhang and e. al, “Zika virus infection induces RNAi-mediated antiviral immunity in human neural progenitors and brain organoids,” Cell Res, pp. 29, 265–273, 2019.
[29] I. Khan, S. Siddiqui, S. Rehmani, S. Kazmi and S. Ali, “Fluoroquinolones inhibit HCV by targeting its helicase,” Antivir. Ther, pp. 17,467, 2012.
[30] M. Yamaya, H. Nishimura, Y. Hatachi, H. Yasuda, X. Deng, T. Sasaki, K. Mizuta, H. Kubo and R.Nagatomi, “Levofloxacin Inhibits Rhinovirus Infection in Primary Cultures of Human Tracheal Epithelial Cells,” Antimicrob. Agents Chemother, pp. 56, 4052–4061., 2012.
[31] F. Touret, M. Gilles, K. Barral, A. Nougairède, J. van Helden, E. Decroly, X. de Lamballerie and B.Coutard, “In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,” Sci.Rep, pp. 10, 1–8, 2020.
[32] D. Kumar, V. Chandel, S. Raj and B. Rathi, “In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach,” Chem. Biol. Lett., p. 166–175, 2020.
[33] K. Marciniec, A. Beberok, P. P˛ecak, S. Boryczka and D. Wrze´sniok, “Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: Preliminary in silico analysis.,” Pharmacol. Rep, pp. 1-9, 2020.
[34] I. Karampela and M. Dalamaga, “Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19?,” Arch.Med.Res, pp. 57, 741–742, 2020.
[35] J. Desmyter, J. Melnick and W. Rawls, “Defectiveness of Interferon Production and of Rubella Virus Interference in a Line of African Green Monkey Kidney Cells (Vero),” J. Virol, pp. 2, 955–961, 1968.
[36] J. Emeny and M. Morgan, “Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production,” J. Gen. Virol, pp. 43, 247–252, 1979.
[37] I. T. S. Y. M. Y. O. G. F. M. Nozaki-Renard J, “Fluoroquinolones Protect the Human Lymphocyte CEM Cell Line from HIV-1-Mediated Cytotoxicity,” Cell Struct Funct, p. 15(5):295–9, 1990.
[38] K. K. H. K. U. J. M. G. Kojima H, “Use of fluoroquinolones in patients with chronic hepatitis C virus- induced liver failure,” Antimicrob Agents Chemother, p. 46(10):3280–2, 2002,Oct.
[39] Y. M. N. C. Ikeda S, “Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative,” Antivir Res, pp. 8(3):103-13, 1987.
[40] O. M. M. M. K. Y. I. T. T. e. a. Baba M, “Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives,” Antimicrob Agents and Chemotherapy, pp. 41(6):1250-5, 1997.
[41] F. F. S. M. M. C. L. A. F. Mottola C, “In vitro antiviral activity of fluoroquinolones against African swine fever virus,” Vet Microbiol, pp. 165(1-2):86-94, 2013.
[42] L. R. B. E. G. T. R. Sharma BN, “Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells,” Antiviral Res, pp. 92(1):115-23, 2011.
[43] T. S. T. M. S. M. Takada A, “Effects of ofloxacin for type C hepatitis,” Int Hepatol Commun, pp.1(5):272-7, 1993.
[44] N. H. H. Y. Y. H. D. X. T. e. a. Yamaya M, “Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells,” Antimicrob Agents and Chemotherapy, pp. 56(8):4052-61, 2012.
[45] Z. J. W. P. M. J. H. R. Anand K, “Coronavirus Main Proteinase (3CL^pro) Structure: Basis for Design of Anti-SARS Drugs,” Science, p. 300(5626):1763, 2003.
[46] B. A. P. P. B. S. W. D. Marciniec K, “Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis,” Pharmacol Rep, pp. 72(6):1553-61, 2020 Dec.
[47] Y. M. N. C. Ikeda S, ” Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative,” Antivir Res, pp. 8(3):103-13, 1987.
[48] D. A, “Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?,” Eur J Clin Microbiol Infect Dis, pp. 34(4):661-8, 2015.
[49] C. A. D. J. Ali SH, ” Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones,” Antivir Ther, p. 12(1):1, 2007.
[50] S. S. R. S. K. S. A. S. Khan IA, “Fluoroquinolones inhibit HCV by targeting its helicase,” Antivir Ther,p. 17(3):467, 2012.
[51] A. E. T. F. Z. A. B. A. R. D. e. a. Umbro I, “Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences,” Virol J, p. 10(1):274, 2013.
[52] N. J. C. Wang, Rev. Mol. Cell Biol, pp. 3, 430, 2003.
[53] D. C. Hooper, Emerg. Infect. Dis, pp. 7, 337, 2001.
[54] A. M. B. C. F. M. R. M. S. A. G. Y. P. a. M. C. M. Nagarajan, J. Med. Chem, pp. 47, 5651, 2004.
[55] A. S. a. A. F. S. Emami, IJPR, pp. 3, 123, 2005.
[56] G. J. F. B. C. B. L. V. D. E. G. a. W. A. J. A. Spicer, Anticancer Drug Des, pp. 14, 37, 1999.
[57] M. L. G. K. S. D. P. Y. N. A. G. P. a. A. W. H. Hentze, Hepatology, pp. 39, 1311, 2004.
[58] N. R. S. B. a. O. L. N. Lebedeva, IUBMB Life, pp. 60,130, 2008.
[59] G. W. N. D. X. W. T. C. S. X. a. W. H. G. Hu, Acta Pharm. Sin B, pp. 2, 312, 2012.
[60] A. S. a. A. F. S. Emami, IJPR, pp. 3,123, 2005.
[61] R. H. S. T. J. A. D. B. a. J. P. D. Chu, Drugs Exp Clin Res, pp. 20,177, 1994.
[62] G. S. B. a. M. R. Hale, Curr. Med. Chem, pp. 23, 520, 2016.
[63] S. W. M.-H. W. M.-L. L. G.-M. X. X.-J. L. Y. C. a. H.-W. H. X.-D. Jia, Chin Chem Lett, pp. 28,235, 2017.
[64] J. A. F. M. P. a. S. A. S. G. C. Jamieson, J. Drug, pp. 76,1245, 2016.
[65] N. G. M. N. R. J. A. B. J. O. a. T. D. T. Kloskowski, Acta Pol Pharm, pp. 68, 859, 2011.
[66] M. O. M. G. H. G. E. H. a. D. S. C. Herold, Br. J. Cancer, pp. 86, 443, 2002.
[67] D. D. N. S. a. E. R. E. Somekh, JPET, pp. 248,415, 1989.
[68] M. L. E. G. E. L. R. W. L. a. L. E. D. T. Miclau, J. Orthop.Res, pp. 16, 509, 1998.
[69] A. S. a. A. F. S. Emami, Mini Rev Med Chem, pp. 6,375, 2006.
[70] Champoux, “J.J. DNA Topoisomerases: Structure, Function and Mechanism,” Annu. Rev. Biochem,pp. 70, 369-413, 2001.
[71] Wang, “J.C. Cellular Roles of DNA Topoisomerases: A Molecular Perspective,” Nat. Rev. Mol. Cell Biol, pp. 3,430-440, 2002.
[72] M. Abdel-Aziz, S.-E. Park, G.-D. Abuo-Rahma, M. Sayed and Y. Kwon, “Novel N-4-Piperazinyl- Ciprofloxacin-Chalcone Hybrids: Synthesis, Physicochemical Properties, Anticancer and Topoisomerase I and II Inhibitory Activity,” Eur. J. Med. Chem, pp. 69, 427-438, 2013.
[73] M. Nagarajan, A. Morrell, B. Fort, M. Meckley, S. Antony, G. Kohlhagen, Y. Pommier and M. Cushman, “Synthesis and Anticancer Activity of Simplified Indenoisoquinoline on the Aromatic Rings,” J. Med. Chem, pp. 47, 5651-5661, 2004.
[74] D. O. N. Burden, “Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.,” Biochim Biophys Acta, pp. 1400 (1-3), 139-54, 1998.
[75] S. Emami, A. Shafiee and A. Foroumadi, “Quinolones: Recent Structural and Clinical Developments,” Iran. J. Pharm. Res, pp. 0, 123-136., 2010.
[76] J. Spicer, G. Finlay, B. Baguley, L. Velea, D. Graves and W. Denny, “5,7-Disubstituted Analogues of the Mixed Topoisomerase I/II Poison N-[2-(Dimethylamino)Ethyl]Acridine-4-Carboxamide (DACA):DNA Binding and Patterns of Cytotoxicity,” Anticancer.Drug Des, pp. 14, 37-45, 1999.
[77] H. Hentze, M. Latta, G. Künstle, S. Dhakshinamoorthy, P. Ng, A. Porter and A. Wendel, “Topoisomerase Inhibitor Camptothecin Sensitizes Mouse Hepatocytes in Vitro and in Vivo to TNF-Mediated Apoptosis,” Hepatol. Baltim. Md, pp. 39, 1311-1320, 2004.